09.18.23
Kyowa Hakko USA has expanded the global reach of its Immuse postbiotic by partnering with Pharmaceutical manufacturer Quifaest to sell it in the Mexican marketplace for the first time. The postbiotic will be featured in immune support supplement Immo Forte.
Immuse was only available in the U.S., Europe, and Canada prior to this partnership.
“Consumers around the globe are looking for new opportunities to elevate their immune health to ensure that they can power through their days feeling their best,” said Karen Todd, MBA, RD, vice president of global brand marketing at Kyowa Hakko USA. “We’re so excited to have partnered with the Quifaest team to give consumers throughout Mexico a novel option with our first launch in this market.”
Immuse has been the subject of 30 published studies, including 15 human clinical trials, which substantiate the postbiotic’s efficacy in supporting healthy immune function. According to the studies, the ingredient has a unique ability to activate plasmacytoid dendritic cells (pDCs).
The pDC, a rare type of immune cell, activates pivotal cells downstream, such as NK, killer-T, helper-T, and B cells.
Quifaest was founded in 2002, and manufactures dietary supplements and pharmaceutical-grade medicinal herbal products.
“I am so glad to announce that Immuse is now available in Mexico,” said Marciano Mateos, CEO of Quifaest Group. “Our corporate mission has found a perfect match with Kyowa. This is a great partnership that will promote dietary supplements that are manufactured with very high-quality ingredients supported by science.”
The product will be sold at the company’s QuifaHealth stores in malls throughout the Mexico City area, with further distribution expected in the future.
Immuse was only available in the U.S., Europe, and Canada prior to this partnership.
“Consumers around the globe are looking for new opportunities to elevate their immune health to ensure that they can power through their days feeling their best,” said Karen Todd, MBA, RD, vice president of global brand marketing at Kyowa Hakko USA. “We’re so excited to have partnered with the Quifaest team to give consumers throughout Mexico a novel option with our first launch in this market.”
Immuse has been the subject of 30 published studies, including 15 human clinical trials, which substantiate the postbiotic’s efficacy in supporting healthy immune function. According to the studies, the ingredient has a unique ability to activate plasmacytoid dendritic cells (pDCs).
The pDC, a rare type of immune cell, activates pivotal cells downstream, such as NK, killer-T, helper-T, and B cells.
Quifaest was founded in 2002, and manufactures dietary supplements and pharmaceutical-grade medicinal herbal products.
“I am so glad to announce that Immuse is now available in Mexico,” said Marciano Mateos, CEO of Quifaest Group. “Our corporate mission has found a perfect match with Kyowa. This is a great partnership that will promote dietary supplements that are manufactured with very high-quality ingredients supported by science.”
The product will be sold at the company’s QuifaHealth stores in malls throughout the Mexico City area, with further distribution expected in the future.
